TP53 and prostate cancer: These results indicate that, in p53-positive DU145 prostate cancer cells GnRH agonists specifically sensitize the cells to the cytotoxic activity of docetaxel; this effect is likely the consequence of the GnRH-A-induced activation of the p38/p53/Bax apoptosis signaling pathway.